1. Home
  2. EXPO vs VKTX Comparison

EXPO vs VKTX Comparison

Compare EXPO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXPO
  • VKTX
  • Stock Information
  • Founded
  • EXPO 1967
  • VKTX 2012
  • Country
  • EXPO United States
  • VKTX United States
  • Employees
  • EXPO N/A
  • VKTX N/A
  • Industry
  • EXPO Professional Services
  • VKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EXPO Consumer Discretionary
  • VKTX Health Care
  • Exchange
  • EXPO Nasdaq
  • VKTX Nasdaq
  • Market Cap
  • EXPO 3.5B
  • VKTX 3.8B
  • IPO Year
  • EXPO 1990
  • VKTX 2015
  • Fundamental
  • Price
  • EXPO $71.64
  • VKTX $34.78
  • Analyst Decision
  • EXPO
  • VKTX Strong Buy
  • Analyst Count
  • EXPO 0
  • VKTX 14
  • Target Price
  • EXPO N/A
  • VKTX $87.00
  • AVG Volume (30 Days)
  • EXPO 385.6K
  • VKTX 4.8M
  • Earning Date
  • EXPO 10-30-2025
  • VKTX 10-22-2025
  • Dividend Yield
  • EXPO 1.65%
  • VKTX N/A
  • EPS Growth
  • EXPO N/A
  • VKTX N/A
  • EPS
  • EXPO 2.03
  • VKTX N/A
  • Revenue
  • EXPO $531,142,000.00
  • VKTX N/A
  • Revenue This Year
  • EXPO $5.31
  • VKTX N/A
  • Revenue Next Year
  • EXPO $7.93
  • VKTX N/A
  • P/E Ratio
  • EXPO $35.91
  • VKTX N/A
  • Revenue Growth
  • EXPO 4.43
  • VKTX N/A
  • 52 Week Low
  • EXPO $63.81
  • VKTX $18.92
  • 52 Week High
  • EXPO $112.75
  • VKTX $79.10
  • Technical
  • Relative Strength Index (RSI)
  • EXPO 64.00
  • VKTX 55.02
  • Support Level
  • EXPO $64.99
  • VKTX $33.00
  • Resistance Level
  • EXPO $70.41
  • VKTX $39.57
  • Average True Range (ATR)
  • EXPO 1.94
  • VKTX 2.28
  • MACD
  • EXPO 0.57
  • VKTX 0.03
  • Stochastic Oscillator
  • EXPO 93.11
  • VKTX 47.31

About EXPO Exponent Inc.

Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Share on Social Networks: